Sugi Predict

Sugi Predict / Compounds / SCHEMBL256048

SCHEMBL256048

SCHEMBL256048

CC/C=C/c1ccccn1

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 4/20 0.62
▸ RAB9A P51151 4/20 0.62
▸ MEN1 O00255 2/20 0.62
▸ KMT2A Q03164 2/20 0.62
▸ ATM Q13315 1/20 0.62
▸ PTGS1 P23219 1/20 0.44
▸ PTGS2 P35354 1/20 0.44
▸ GRM4 Q14833 1/20 0.44
▸ NR4A1 P22736 1/20 0.44
▸ MAOA P21397 1/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ TOP2A P11388 1/20 0.41
▸ MAPT P10636 2/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ NFE2L2 Q16236 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL456987 1.00 NPC1 (0.62) NPC1RAB9AMEN1KMT2AATM
SCHEMBL2660767 0.83 MEN1 (0.58) NPC1RAB9AMEN1KMT2AATM
SCHEMBL2660769 0.83 MEN1 (0.58) NPC1RAB9AMEN1KMT2AATM
SCHEMBL30379649 0.83 MEN1 (0.58) NPC1RAB9AMEN1KMT2AATM
SCHEMBL270008 0.82 — —
SCHEMBL2821529 0.81 NPC1 (0.46) NPC1RAB9AMEN1KMT2AATM
SCHEMBL6863156 0.80 MEN1 (0.54) NPC1RAB9AMEN1KMT2AATM
SCHEMBL6863164 0.80 MEN1 (0.54) NPC1RAB9AMEN1KMT2AATM
SCHEMBL13699261 0.79 NPC1 (0.52) NPC1RAB9AMEN1KMT2AATM
SCHEMBL9466506 0.79 MEN1 (0.52) NPC1RAB9AMEN1KMT2AATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116715622-A Synthesis method of 2- (2-arylbutyl) pyridine compound 河南大学 2023-09-08 — — CN disclosed
US-20220153732-A1 PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2022-05-19 — — US disclosed
EP-3313837-B1 CARBOLINE ANTIPARASITICS ZOETIS SERVICES LLC (US) 2020-09-09 — — EP disclosed
US-10570129-B2 Carboline antiparasitics ZOETIS SERVICES LLC (US) 2020-02-25 — — US disclosed
US-20200031822-A1 CARBOLINE ANTIPARASITICS ZOETIS SERVICES LLC (US) 2020-01-30 — — US disclosed
EP-3313837-A1 CARBOLINE ANTIPARASITICS Zoetis Services LLC (US) 2018-05-02 — — EP disclosed
EP-3153023-A1 BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE Intellikine, LLC (US) 2017-04-12 — — EP disclosed
WO-2016209635-A1 CARBOLINE ANTIPARASITICS ZOETIS SERVICES LLC (US) 2016-12-29 — — WO disclosed
US-20120276050-A1 METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2012-11-01 — — US disclosed
US-20120263771-A1 FIBER WITH MICROBIAL REMOVAL, MICRO-BIOCIDAL, OR STATIC GROWTH CAPABILITY RECEPTORS LLC (US) 2012-10-18 — — US disclosed
WO-1998025872-A1 SUBSTANCE MIXTURES CONTAINING STABILIZERS AND COMPOUNDS CONTAINING VINYL GROUPS BASF AKTIENGESELLSCHAFT (DE) 1998-06-18 — — WO disclosed
WO-1998025601-A1 FIBRINOGEN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1998-06-18 — — WO disclosed
US-5733919-A Compositions for inhibiting platelet aggregation MERCK & CO., INC. (US) 1998-03-31 — — US disclosed
WO-1998000134-A1 FIBRINOGEN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1998-01-08 — — WO disclosed
WO-1998000144-A1 FIBRINOGEN RECEPTOR ANTAGONIST PRODRUGS MERCK & CO., INC. (US) 1998-01-08 — — WO disclosed
WO-1998000401-A1 FIBRINOGEN RECEPTOR ANTAGONIST PRODRUGS MERCK & CO., INC. (US) 1998-01-08 — — WO disclosed
WO-1997046504-A1 MIXTURES CONTAINING MONOMERS AND STABILIZERS BASF AKTIENGESELLSCHAFT (DE) 1997-12-11 — — WO disclosed
WO-1997026250-A1 INTEGRIN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1997-07-24 — — WO disclosed
WO-1997015328-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING PLATELET AGGREGATION INHIBITORS MERCK & CO., INC. (US) 1997-05-01 — — WO disclosed
WO-1997014417-A1 FIBRINOGEN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1997-04-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120263771-A1 FIBER WITH MICROBIAL REMOVAL, MICRO-BIOCIDAL, OR STATIC GROWTH CAPABILITY MFAP1, MGAM, MIF NPC1 4272/4885RAB9A 1957/4885MEN1 687/4885
US-20220153732-A1 PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G NPC1 407/4885RAB9A 222/4885MEN1 1347/4885
US-10570129-B2 Carboline antiparasitics ADRA1D, DRD1, CHRM1 NPC1 1667/4885RAB9A 272/4885MEN1 1206/4885
US-20200031822-A1 CARBOLINE ANTIPARASITICS DRD1, ADRA1D, DRD2 NPC1 1255/4885RAB9A 520/4885MEN1 1536/4885
US-20120276050-A1 METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION NSUN3, RNGTT, NSUN2 NPC1 847/4885RAB9A 3558/4885MEN1 4872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.